Ipsen ends neu­ro­tox­in pact with Gal­der­ma af­ter ar­bi­tra­tion cas­es filed in in­ter­na­tion­al court

Ipsen has ter­mi­nat­ed a 2014 neu­ro­tox­in R&D deal with Gal­der­ma af­ter the part­ner start­ed two cas­es at the In­ter­na­tion­al Cham­ber of Com­merce against Ipsen, the com­pa­ny said in its earn­ings state­ment Wednes­day.

Ipsen CEO David Loew said on a me­dia call that the com­pa­ny let Gal­der­ma know about the ter­mi­na­tion on Wednes­day night. The com­pa­ny plans to “ful­ly de­fend and vin­di­cate its rights” in the ICC cas­es, the com­pa­ny said in a state­ment. Ipsen CFO Aymer­ic le Chate­lier said the ar­bi­tra­tion is ex­pect­ed to fin­ish by the end of the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER